Penumbra Debt to Equity Ratio 2014-2022 | PEN
Current and historical debt to equity ratio values for Penumbra (PEN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Penumbra debt/equity for the three months ending September 30, 2022 was 0.03.
| Penumbra Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-09-30 |
$0.35B |
$0.97B |
0.36 |
| 2022-06-30 |
$0.36B |
$0.97B |
0.37 |
| 2022-03-31 |
$0.34B |
$0.96B |
0.36 |
| 2021-12-31 |
$0.29B |
$0.95B |
0.30 |
| 2021-09-30 |
$0.29B |
$0.69B |
0.42 |
| 2021-06-30 |
$0.24B |
$0.67B |
0.35 |
| 2021-03-31 |
$0.19B |
$0.65B |
0.29 |
| 2020-12-31 |
$0.19B |
$0.64B |
0.29 |
| 2020-09-30 |
$0.19B |
$0.62B |
0.31 |
| 2020-06-30 |
$0.16B |
$0.62B |
0.25 |
| 2020-03-31 |
$0.18B |
$0.49B |
0.36 |
| 2019-12-31 |
$0.18B |
$0.49B |
0.37 |
| 2019-09-30 |
$0.15B |
$0.47B |
0.32 |
| 2019-06-30 |
$0.13B |
$0.45B |
0.29 |
| 2019-03-31 |
$0.13B |
$0.44B |
0.30 |
| 2018-12-31 |
$0.09B |
$0.42B |
0.22 |
| 2018-09-30 |
$0.09B |
$0.41B |
0.22 |
| 2018-06-30 |
$0.07B |
$0.43B |
0.17 |
| 2018-03-31 |
$0.08B |
$0.42B |
0.18 |
| 2017-12-31 |
$0.08B |
$0.40B |
0.19 |
| 2017-09-30 |
$0.08B |
$0.38B |
0.20 |
| 2017-06-30 |
$0.04B |
$0.37B |
0.12 |
| 2017-03-31 |
$0.05B |
$0.37B |
0.12 |
| 2016-12-31 |
$0.04B |
$0.27B |
0.16 |
| 2016-09-30 |
$0.04B |
$0.25B |
0.17 |
| 2016-06-30 |
$0.04B |
$0.25B |
0.15 |
| 2016-03-31 |
$0.04B |
$0.24B |
0.16 |
| 2015-12-31 |
$0.03B |
$0.23B |
0.14 |
| 2015-09-30 |
$0.03B |
$0.23B |
0.13 |
| 2015-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2015-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2014-12-31 |
$0.00B |
|
0.00 |
| 2014-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2013-12-31 |
$0.02B |
$0.05B |
0.48 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$9.289B |
$0.748B |
|
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.
|
